Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.20.2
Revenue (Tables)
9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended September 30, Nine Months Ended September 30,
  2020 2019 2020 2019
Seagen $ 366  $ 576  $ 9,326  $ 2,005 
AstraZeneca 2,182  2,903  7,227  12,811 
Servier 391  11,653  10,893  14,193 
Total Revenue $ 2,939  $ 15,132  $ 27,446  $ 29,009 
Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,111  $ 960 
Servier 712  632 
Seagen 764  450 
Total potential milestone payments $ 2,587  $ 2,042